Oxidation of intramyocellular lipids is dependent on mitochondrial function and the availability of extracellular fatty acids by Corpeleijn, Eva et al.
Oxidation of intramyocellular lipids is dependent on mitochondrial function
and the availability of extracellular fatty acids
Eva Corpeleijn,1 Nina P. Hessvik,2 Siril S. Bakke,2 Klaus Levin,3 Ellen E. Blaak,1 G. Hege Thoresen,2
Michael Gaster,3 and Arild C. Rustan2
1Department of Human Biology, Maastricht University, Nutrition and Toxicology Research Institute Maastricht, Maastricht,
The Netherlands; 2Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway;
and 3Klinik for Molekylær Endokrinologisk Behandling, Department of Endocrinology, Odense University Hospital,
Odense, Denmark
Submitted 24 March 2010; accepted in final form 3 May 2010
Corpeleijn E, Hessvik NP, Bakke SS, Levin K, Blaak EE, Thore-
sen GH, Gaster M, Rustan AC. Oxidation of intramyocellular lipids is
dependent on mitochondrial function and the availability of extracellular
fatty acids. Am J Physiol Endocrinol Metab 299: E14–E22, 2010. First
published May 4, 2010; doi:10.1152/ajpendo.00187.2010.—Obesity and
insulin resistance are related to both enlarged intramyocellular triac-
ylglycerol stores and accumulation of lipid intermediates. We inves-
tigated how lipid overflow can change the oxidation of intramyocel-
lular lipids (ICLOX) and intramyocellular lipid storage (ICL). These
experiments were extended by comparing these processes in primary
cultured myotubes established from healthy lean and obese type 2
diabetic (T2D) individuals, two extremes in a range of metabolic
phenotypes. ICLs were prelabeled for 2 days with 100 M [14C]oleic
acid (OA). ICLOX was studied using a 14CO2 trapping system and
measured under various conditions of extracellular OA (5 or 100 M)
and glucose (0.1 or 5.0 mM) and the absence or presence of mito-
chondrial uncoupling [carbonyl cyanide p-trifluoromethoxyphenylhy-
drazone (FCCP)]. First, increased extracellular OA availability (5 vs.
100 M) reduced ICLOX by 37%. No differences in total lipolysis
were observed between low and high OA availability. Uncoupling
with FCCP restored ICLOX to basal levels during high OA availabil-
ity. Mitochondrial mass was positively related to ICLOX, but only in
myotubes from lean individuals. In all, a lower mitochondrial mass
and lower ICLOX were related to a higher cell-associated OA accu-
mulation. Second, myotubes established from obese T2D individuals
showed reduced ICLOX. ICLOX remained lower during uncoupling
(P  0.001), even with comparable mitochondrial mass, suggesting
decreased mitochondrial function. Furthermore, the variation in
ICLOX in vitro was significantly related to the in vivo fasting respi-
ratory quotient of all subjects (P  0.02). In conclusion, the rate of
ICLOX is dependent on the availability of extracellular fatty acids and
mitochondrial function rather than mitochondrial mass.
lipid overflow; mitochondria; lipid oxidation; metabolic flexibility
SKELETAL MUSCLE INSULIN RESISTANCE is a central pathophysio-
logical feature of type 2 diabetes (T2D) mellitus, and increas-
ing evidence has shown that it is associated with increased
intramyocellular lipid (IMCL) content. The precise molecular
mechanisms underlying this relationship are not known but
may involve the accumulation of lipid intermediates that either
interfere with the insulin-signaling pathway and/or induce inflam-
matory pathways (1, 12, 22). The accumulation of IMCLs and
lipid intermediates may be due to a mismatch between lipid
storage, lipolysis, and oxidation (28). Elevation of plasma fatty
acid concentration, so-called lipid overflow, may enhance
IMCL accumulation and induce insulin resistance, as shown in
lipid infusion studies (6, 36). Several animal models show that
an improved fat oxidation can prevent high-fat diet-induced
insulin resistance (8, 24). More specifically a reduced capacity
to oxidize IMCLs may contribute to intracellular accumulation
of lipids and lipid intermediates. It is unknown to what extent
lipid overflow (i.e., increased extracellular fatty acid availabil-
ity), mitochondrial function, and the oxidation of intracellular
lipids contribute to IMCL accumulation.
Multiple studies have shown that fatty acid handling is
impaired in skeletal muscle of obese, impaired glucose-toler-
ant, and T2D individuals (3, 9, 10, 25, 26), which may be due
to a primary genetic component. A promoter polymorphism in
the gene for the fatty acid transporter CD36 was associated
with a decreased insulin sensitivity and an increased preva-
lence of T2D (11). Despite significant weight loss, a lack of
improvement in the ability to increase fat oxidation during
-adrenergic stimulation in obese subjects was observed (4),
and under similar conditions the ability to increase fat oxida-
tion during exercise in T2D individuals remained impaired (5).
A reduced ability to stimulate fat oxidation during exercise
(26) and to switch between lipids and carbohydrates for fuel
after a meal (9) was already present in “prediabetic” impaired
glucose-tolerant subjects. In vitro experiments with myotubes
established from diabetic patients show a lower baseline palmi-
tate oxidation during acute palmitate exposure relative to
cultured myotubes from body mass index-matched controls
(19, 20, 40). Whether a primary defect in IMCL oxidation may
play a role in the development of diabetes is unknown.
To study both primary and secondary impairments in fatty
acid handling, cultured human myotubes represent a well-
characterized in vitro model of skeletal muscle. The advan-
tages of using human myotubes is that the extracellular envi-
ronment can be controlled precisely and kept constant over
time, which allows for studying the importance of the intrinsic
characteristics without systemic homeostatic regulatory com-
ponents from the nervous and endocrine systems. It has been
used previously to study the separate contributions of intracel-
lular and extracellular substrates on total substrate oxidation
(13). Moreover, previous studies in these cultured myotubes
have shown that the insulin-resistant phenotype is conserved
(15, 18). In the present study, we took advantage of this model
to investigate the effects of extracellular fatty acids, glucose,
and mitochondrial uncoupling [carbonyl cyanide p-trifluoro-
methoxyphenylhydrazone (FCCP)] on oxidation of intracellu-
lar lipids (ICLOX) and to compare these effects in primary
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myotubes established from healthy lean with those from obese
T2D individuals.
MATERIALS AND METHODS
Materials. Dulbecco’s modified Eagle’s medium (DMEM-Glu-
tamax), DMEM without phenol red (Sigma D5030), non-heat-inacti-
vated fetal calf serum (FCS), and penicillin-streptomycin-amphoteri-
cin B were purchased from GIBCO Invitrogen (GIBCO Life Tech-
nologies, Paisley, UK). Bovine serum albumin (BSA; essentially fatty
acid free), L-carnitine, Dulbecco’s phosphate-buffered saline (DPBS;
with Mg2 and Ca2), oleic acid (OA), extracellular matrix (ECM)
gel, and HEPES were purchased from Sigma (St. Louis, MO). Ul-
troser G was purchased from Ciphergen (Cergy-Saint-Christophe,
France), and insulin (Actrapid) was purchased from Novo Nordisk
(Bagsvaerd, Denmark). [1-14C]OA (55 mCi/mmol) was purchased
from American Radiolabeled Chemicals (St. Louis, MO). Corning
CellBIND tissue culture plates were obtained from Corning Life
Sciences (Schiphol-Rijk, The Netherlands). Glass bottom plates were
from MatTek (Ashland, MA). OptiPhase Supermix, UniFilter-96
GF/B plates, and ScintiPlates were delivered by PerkinElmer (Shel-
ton, CT). Protein assay kit was purchased from Bio-Rad (Copenhagen,
Denmark). Bodipy 493/503 (4,4-difluoro-1,3,5,7,8-pentamethyl-4-
bora-3a,4a-diaza-s-indacene), MitoTracker Red FM, and Hoechst
33258 were obtained from Molecular Probes (Invitrogen, Carlsbad,
CA). All other chemicals used were of standard commercial high-
purity quality.
Characterization of the donors. To establish primary myotube
cultures, muscle biopsies were taken from M. vastus lateralis by
needle biopsy according to Bergstrom (2) in 17 Caucasian partici-
pants, of which eight were lean healthy glucose-tolerant controls (5
males, 3 females) without family history of T2D and nine were obese
subjects with T2D (5 males, 4 females). The characteristics of the
participants are shown in Table 1. Initially, nine lean controls were
included, but from one of the lean subjects (female) the myotubes
showed insufficient growth for reliable measurements. Subjects re-
frained from strenuous physical activity 3 days before metabolic
investigations. Diabetic subjects were treated with diet alone or in
combination with sulfonylurea, metformin, or insulin, which was
withdrawn 1 wk before biopsies were taken. None of the subjects
suffered from diseases other than diabetes and hypertension. Insulin
sensitivity was determined by hyperinsulinemic euglycemic clamp
(40 mU·m2·min1) (21). Respiratory quotients (RQ) were calculated
from substrate oxidation rates measured by indirect calorimetry (Del-
tatrac; Datex, Helsinki, Finland) with adjustments for protein oxida-
tion. Metabolic flexibility was calculated as fasting RQ minus RQ
during clamp. All subjects gave written, informed consent, and the
local ethics committee of Funen and Vejle County approved the study.
Cell culture. Muscle cell cultures were established as described
previously (16, 17). In brief, muscle biopsy tissue was minced and
washed, and cells were dissociated for 60 min by three treatments with
0.05% trypsin-EDTA. The harvested cells were pooled, and FCS was
added to stop trypsinization. The isolated satellite cells (muscle
precursor cells) were proliferated and stored in liquid nitrogen until
further use. For experiments, cells were grown on 12-, 24-, or 96-well
plates with DMEM-Glutamax (5.5 mM glucose), 2% FCS, 2% Ul-
troser G, P/S, and amphotericin B until 70–80% confluence. Myo-
blast differentiation to myotubes was then induced by changing
medium to DMEM-Glutamax supplemented with 2% FCS, P/S, 1.25
g/ml amphotericin B, and 25 pM insulin. The cells were cultured in
a humidified 5% CO2 atmosphere at 37°C, and the medium was
changed every 2–3 days. Experiments were performed after 7 days of
differentiation, and preincubation with fatty acid was started after 5
days.
Experimental setup. In the present study, a crossover design was
used as explained in Fig. 1. After 5 days of differentiation, the cells
were pretreated with 100 M OA for 2 days (48 h) and then treated
acutely for 4 h with varying concentrations of OA (5 or 100 M; f or
F, respectively) and glucose (0.1 or 5.0 mM; g or G, respectively).
These concentrations were chosen on the basis of uptake rates rather
Table 1. Clinical characteristics of the study subjects
All (n  17) Range Lean (n  8) Obese T2D (n  9)
Age, yr 50.7 1.0 43–58 51.4 0.9 50.0  1.6
Body mass index, kg/m2 29.0  1.4 21–39 23.7 0.5 33.7  1.3*
Fasting plasma glucose, mM 7.9 0.6 5.3–12.9 5.7  0.1 9.8  0.7*
Fasting insulin, pM 50.0 8.1 9–100 18.8 3.0 75.0  7.8*
Glucose infusion rate, mg  min1  m2 246  34 55–487 378  25 129  16*
Hb A1c, % 6.4  0.4 5.1–10.6 5.6  0.1 7.4  0.6†
Total cholesterol, mM 5.3 0.2 3.9–7.2 5.3  0.3 5.2  0.4
LDL cholesterol, mM 3.1 0.2 1.8–4.3 3.0  0.3 3.1  0.3
HDL cholesterol, mM 1.6 0.1 1.2–2.5 1.9  0.1 1.4  0.1†
Fasting triacylglycerol, mM 1.3 0.2 0.7–3.8 1.0  0.1 1.6  0.3
RQfasting 0.79  0.01 0.74–0.87 0.80 0.01 0.78 0.01
Metabolic flexibility (RQclamp  RQfasting) 0.10  0.02 0.00–0.29 0.16 0.03 0.05 0.01‡
Values represent means  SE and range (minimum to maximum) for all individuals together and lean and obese type 2 diabetic individuals separately.
RQfasting, fasting respiratory quotient; RQclamp, clamp respiratory quotient. *P  0.001; †P  0.02; ‡P  0.01 vs. lean subjects.
Fig. 1. Experimental setup. All cells were pretreated for 2 days with 100 M
oleic acid (OA), either unlabeled or enriched with [14C]OA (1.5–2.2 Ci/ml;
labeling marked with an asterisk). Then, all cells underwent CO2 trapping for
4 h in 4 different acute conditions, as explained above, with [14C]OA-enriched
medium or with medium containing unlabeled OA. A crossover design was
used, so all of the cells underwent pretreatment and the acute experiment but
were presented with [14C]OA either during pretreatment or during the 4 h of
CO2 trapping. During the 4 h of acute CO2 trapping, 14CO2 from either
intracellular lipids (OA* pretreatment) or extracellular lipids (OA* acute
conditions) were trapped to distinguish between oxidation of lipids from
intracellular or extracellular sources, respectively.
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than on imitation of plasma values. The acute treatments were chosen
to mimic various physiological conditions for skeletal muscle cells,
such as the fed state [high glucose supply, low free fatty acid (FFA)
availability] and fasting (high FFA uptake, low glucose transport), and
other combinations to study the response on lipid oxidation (e.g.,
adaptability to increased fatty acid availability and suppressibility of
glucose on fatty acid oxidation when being changed from low to high
concentrations).
During the 4-h acute experiment, the production of 14CO2 was
measured as described under the heading substrate oxidation assay. To
distinguish between 14CO2 production from intracellular (ICLOX) or
extracellular sources (ECLOX), labeling with [1-14C]OA was applied
in the medium immediately at the start during pretreatment (14CO2
comes from intracellular lipids) or during the acute experiment
(14CO2 is medium derived). The cells were washed twice with PBS
after pretreatment, before addition of acute medium for CO2 trapping.
Substrate oxidation assay. Substrate oxidation was monitored by
incubating cells grown on 96-well plates (CellBIND) with [14C]OA,
with subsequent capture of liberated 14CO2 for 4 h at 37°C, using a
“sandwich” clamp instrument, as described previously (41). Radioac-
tivity in the filter wells was counted in a scintillation counter for
multiwell plates (MicroBeta; PerkinElmer). Immediately after 14CO2
trapping, the cells were washed two times with PBS and harvested
with 0.1 M NaOH (200 l/well). Protein was determined by Coomas-
sie reagent (7). For total (cell-associated) accumulation of [14C]OA,
50 l cell homogenate/sample was added to scintillation fluid and
counted (MicroBeta).
Scintillation proximity assay. Radiolabeled substrates taken up
and accumulated by adherent cells were concentrated close to the
scintillator embedded in the plastic bottom of each well and thus
provided a stronger signal than the radiolabel dissolved in the
medium alone (41). Measurements of OA uptake by scintillation
proximity assay (SPA) were performed in DME-medium, using
96-well ScintiPlates (http://www.perkinelmer.com for SPA tech-
nology; Perkin-Elmer) as described above without phenol red, with
an additional 100 M OA (1.5–2.2 Ci/ml [1-14C]OA) bound to
BSA at a ratio of 2.5:1.
Lipid distribution. Myotubes grown on 12-well plates were
pretreated with [1-14C]OA (100 M) for 48 h. After the acute
experiment (4 h), cells were washed twice with PBS, harvested in
distilled water (200 l), and stored at 20°C for extraction of
cellular lipids (19). Briefly, the homogenized cell fraction was
mixed with 20 volumes of chloroform-methanol (2:1), and FCS (30
l) was added as a lipid carrier. After 30 min, four volumes of
0.9% NaCl (pH 2) was added and the mixture was centrifuged
(1,000 g, 5 min). The organic phase was evaporated under a
nitrogen steam at 40°C. The residual lipid extract was redissolved
in 150 l of n-hexane and separated by thin-layer chromatography
(TLC) using hexane-diethylether-acetic acid (65:35:1) as mobile
phase. The lipid bands were visualized with iodine and excised,
and radioactivity was quantified by liquid scintillation. The lipid
classes were identified with standards.
Determination of lipolysis. Cells grown on 96-well plates (Cell-
BIND) were pretreated with [1-14C]OA (1.5 Ci/ml, 100 M) for 48
h to prelabel the endogenous triacylglycerol (TAG) pool. Following
preincubation, myotubes were incubated for 4 h in DPBS with 2%
BSA (fatty acid free) and 10 M triacsin C to block fatty acid
recycling into the TAG pool and oxidation. Lipolysis was performed
under the gf (0.1 mM glucose/5 M OA) and GF (5.0 mM glucose/
100 M OA) conditions. At the end of incubation, medium was
collected and cells harvested for scintillation counting. Protein was
determined by Coomassie reagent (7).
Mitochondrial uncoupling. Cells grown on 96-well plates were
exposed to pretreatment and acute treatment as described under
experimental setup, with the exception of now using gf, gF (0.1 mM
glucose/100 M OA), and GF as acute conditions. During the acute
experiment, myotubes were incubated in the presence and absence of
1 M FCCP, a mitochondrial protonophore. OA uptake and oxidation
were measured as described under substrate oxidation assay.
Live imaging of lipid droplets and mitochondria. Myotubes were
cultured and pretreated with 100 M OA for 48 h using 24-well glass
bottom plates (MatTek) with ECM coating. Myotubes were incubated
with Bodipy 493/503 (2 g/ml) for 5 min to stain lipid droplets (LDs),
with MitoTracker Red FM (100 nM) for 15 min to stain mitochondria,
and with Hoechst (2.5 g/ml) for 15 min to stain the nuclei. Auto-
mated image acquisition was performed with an Olympus Scan^R
platform (Olympus IX81 inverted fluorescence microscope with a
computer-controlled motorized stage) equipped with a temperature
and CO2 enrichment incubator for long-term live imaging. We used a
20 objective and standard filter sets with excitation window for
Hoechst (350 nm), Bodipy 493/503 (488 nm), and MitoTracker Red
FM (594 nm) and a triple band filter for emission. Images were taken
in 25 positions/well, 2 wells/donor, and each image was the back-
ground-subtracted maximal intensity projection from 12 images taken
in z-direction (1 m apart), where one image contained 52  2 nuclei
on average. Scan^R software was used for automated image analysis,
using edge detection algorithm for object segmentation to quantify the
number of nuclei, density, diameter, and number of LDs and total
mitochondrial mass (total intensity of MitoTracker Red).
Presentation of data and statistics. All values are reported as means 
SE. The value n represents the number of different donors used.
Linear mixed models were used to compare the differences between
conditions with within-donor variation and simultaneously compare
differences between groups with between-donor variation. The linear
mixed models include all observations in the statistical analyses and at
the same time take into account that not all observations are indepen-
dent. Correlations are presented as Spearman’s correlation coefficient
(r). Clinical data were compared with two-tailed, unpaired Student’s
t-test. The statistical analyses were performed with SPSS version 12
(SPSS, Chicago, IL). P  0.05 was considered significant.
RESULTS
Experimental setup: fatty acid uptake, accumulation, and
prelabeling of myotubes. Isotopic equilibrium of the intracel-
lular lipid pool (label entering the pool equals label leaving the
pool) reached a plateau after 	48 h (Fig. 2A). Lipid accumu-
lation measured as the cell-associated radioactivity and as the
number of LDs (Fig. 3) per nucleus was not significantly
different between myotubes from lean and obese T2D subjects
(Fig. 2, B and C). The average LD sizes were 1.7  0.1 and
1.8  0.1 m3 for T2D and lean, respectively (P  0.31). The
density of LDs was measured as fluorescence intensity per LD,
showing no significant differences between T2D and lean
subjects (data not shown). Furthermore, intracellular lipid dis-
tribution was assessed by TLC in myotubes from lean subjects
(n  4) after 48 h of pretreatment with labeled OA and 4 h of
acute experiments (see Fig. 1 for conditions). Most of the
cell-associated lipids were represented by triacylglycerols (53–
61%), FFAs (25–33%), and to a lesser extent diacylglycerols
(6–7%), phospholipids (2–4%), and cholesteryl esters (3–4%).
There was no significant effect of the different acute treatments
on intracellular lipid distribution.
Mitochondrial mass by live imaging. After 48-h treatment
with 100 M OA, mitochondrial mass, measured as total
intensity of MitoTracker Red FM per nucleus, was not differ-
ent between myotubes from the two donor groups (fluores-
cence intensity: 611  72  103 AU in T2D and 482  34 
103 AU in lean, P  0.14; for images, see Fig. 3).
Oxidation of lipids. In myotubes from obese T2D subjects,
the ICLOX (Fig. 4A), ECLOX (Fig. 4C), and total lipids (sum of
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ICLOX and ECLOX; Fig. 4D) were systematically reduced in all
four of the acute conditions compared with myotubes from lean
subjects. Also, ICLOX adjusted for differences in total ICL
content (cell-associated radioactivity) was systematically re-
duced in T2D myotubes (Fig. 4B). This indicates that a general
defect in lipid oxidation can be extended to a reduced oxidation
of intracellular lipids. Increasing the concentration of extracel-
lular fatty acid markedly increased extracellular lipid oxidation
(ECLOX) and total lipid oxidation (TLOX) (Fig. 4, C and D).
The increase in ECLOX and TLOX upon increased fatty acid
availability was smaller in myotubes from obese T2D subjects
compared with myotubes from lean subjects at both 0.1 (g) and
5.0 (G) mM extracellular glucose (P  0.05; Fig. 4, E and F,
respectively). Cell-associated OA from the acute incubations
was not different between myotubes from the two donor groups
(data not shown).
Effects of extracellular fatty acids, glucose, and mitochon-
drial uncoupling on ICLOX. Figure 5 shows the relative change
in substrate oxidation upon increases in glucose and fatty acid
availability, taking the “gf” condition as the reference. Figure
5A shows that in the presence of extracellular fatty acids the
ICLOX was lower (in the 100-M condition “F” compared with
the 5-M condition “f”; P  0.001) in myotubes from lean
individuals (32%) and in myotubes from T2D individuals
(46%). Figure 5B shows that a higher concentration of
glucose has a similar but smaller effect and significantly
suppressed ICLOX in the T2D cells (24%, P 0.05; Fig. 5B),
but not in lean cells (12%). Overall, the suppressive effects
of extracellular OA and glucose on intracellular lipid utiliza-
tion were significantly stronger in myotubes established from
obese T2D subjects (P  0.002). Figure 5C shows the effects
after mitochondrial respiration was increased by addition of the
mitochondrial uncoupler FCCP. The suppressive effect of
increased extracellular fatty acid availability was still present
when mitochondrial oxidative capacity (electron transport
chain flux) was increased by FCCP. Figure 5C also shows that
increased mitochondrial oxidative respiration by FCCP re-
stored ICLOX in the presence of increased extracellular fatty
acid availability (gF/FCPP and GF/FCPP) to the level of
low fatty acid availability (gf/FCPP), at least in myotubes
from lean subjects. In the presence of FCCP, ICLOX was
increased significantly for both groups at all acute conditions
examined. The relative effect of FCCP on ICLOX is presented
in Fig. 5D. The uncoupling effect of FCCP overall was 14%
lower in myotubes from T2D compared with lean donors (P 
0.04; Fig. 5D), suggesting a primary reduced mitochondrial
capacity despite comparable mitochondrial mass.
Correlations with in vivo characteristics. To examine
whether intrinsic characteristics of the myotubes in vitro were
reflected by the phenotype of the donor in vivo, lipid oxidation
Fig. 2. Prelabeling of myotubes with OA. A: isotopic equilibrium of the intracellular lipid pool (label entering the pool equals label leaving the pool) was assessed
by following real-time accumulation of [14C]OA (100 M) in differentiated myotubes from lean control subjects (n  2, using 8 wells/donor) for 54 h, using
a scintillation proximity assay. B: accumulation of [14C]OA after 48 h of incubation (100 M) and 4 h of incubation with unlabeled OA in the 4 different acute
conditions (means  SE). No significant differences between groups were observed (P  0.22). Open bars represent lean subjects (n  8), and black bars
represent obese type 2 diabetic (T2D) subjects (n  9). For explanation of abbreviations, see legend to Fig. 1. Results represent means  SE, with each donor
(n 8–9) quantified from 8 wells/condition. C: no. of lipid droplets (LDs) per nucleus (see MATERIALS AND METHODS). The myotubes from lean and T2D subjects
were pretreated for 48 h with 100 M OA. The absolute values of LDs per nucleus were in the range of 5 to 118. Results represent means  SE for 6 different
donors/group, quantified from 2 wells/donor, using 25 images/well.
Fig. 3. Staining and live cell imaging of LDs
and mitochondria. Myotubes were pretreated
with 100 M OA for 48 h. The cells were
stained for nuclei (blue), mitochondria (red),
and LDs (green), as described in MATERIALS
AND METHODS. Representative images are
presented for lean (A) and obese T2D myo-
tubes (B). Scale bar, 50 m.
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parameters (ICLOX, ECLOX, total CO2 production) and lipid
accumulation (cell-associated lipids after pretreatment and
acute conditions) were studied in relation to in vivo substrate
metabolism, represented by fasting RQ, RQ during the hyper-
insulinemic euglycemic clamp, and the change in RQ from the
fasted to the insulin-stimulated state (metabolic flexibility).
The correlations were studied in the total group (n  17).
The in vivo fasting RQ was consistently inversely associ-
ated with outcomes for in vitro lipid oxidation, including the
ICLOX under all conditions and the ECLOX under increased
OA (100 M) conditions (gF and GF) (Spearman rALL 

0.59, PALL  0.05). Examples of these associations are
given in Fig. 6, A and B, representing the association
between in vivo fasting RQ with in vitro ICLOX or in vitro
total lipid oxidation, respectively.
Lipolysis. Lipolysis of intracellular prelabeled lipids was
measured in myotubes from lean subjects to study whether a
product inhibition of lipolysis by extracellular fatty acids could
explain the reduction in ICLOX. It was found that basal lipol-
ysis of ICL (in the presence of triacsin C) was not different
between the gf (180 26 nmol/mg protein) and GF (169 28
nmol/mg protein) conditions, respectively. Over 4 h, the
amount of OA released from ICL was 45% of the total OA
present in the cells (data not shown). This suggests that the
availability of ICL-derived fatty acids is not directly limiting
ICLOX.
ICLOX, mitochondrial function, and IMCL accumulation. To
identify which factors regulate ICLOX and cell-associated OA
accumulation, correlations were studied (Fig. 7). Since there is
a broad variation in the cellular phenotype and a large degree
of overlap in these parameters, the groups were analyzed
together. In linear mixed-model analyses, taking into account
the repeated measurements of the cell-associated OA accumu-
lation and ICLOX under the various acute conditions, the
accumulation of OA was inversely related to mitochondrial
mass (P  0.001) and ICLOX (P  0.003). Both factors
contributed independently. Mitochondrial mass was not di-
rectly related to ICLOX in the group as a whole but was
strongly related in myotubes from lean subjects only (Fig. 7A).
Furthermore, an increased intramyocellular OA accumulation
was strongly related to a larger LD size (Spearman r  0.66,
P  0.02, n  12; Fig. 7B).
DISCUSSION
The findings of the present study suggest that elevated
extracellular fatty acids suppress the oxidation of intramyocel-
lular lipids. This is not because of an effect of extracellular
lipids on ICL lipolysis. Mitochondrial uncoupling can coun-
teract the effect and increase ICLOX to basal levels under
conditions of high extracellular fatty acid availability. A re-
duced oxidation of ICL and reduced mitochondrial mass were
shown to contribute independently to accumulation of in-
tramyocellular lipids. Furthermore, the capacity to oxidize ICL
and to increase ECLOX upon increased fatty acid availability is
reduced in myotubes established from obese T2D individuals
despite comparable mitochondrial mass. The finding that lipid
oxidation in vitro was inversely related to fasting RQ in vivo
supports the idea that the primary impairments observed
in vitro are relevant for the in vivo phenotype.
An important observation is that when fatty acid availability
is high, the oxidation of intracellular lipids is decreased. In
general, most fatty acids that are taken up in skeletal muscle
are shuttled toward oxidation (Fig. 8A). In subjects with a
reduced capacity for lipid oxidation, a larger part of the fatty
acids taken up may be shuttled toward storage (Fig. 8B). In the
Fig. 4. Effects of substrate availability on lipid oxidation. Lipid oxidation
after 4 h of CO2 trapping under conditions that vary in glucose and fatty
acid availability in myotubes from lean and T2D subjects. The cells were
incubated with [14C]OA, as described in Fig. 1. Open bars represent lean
subjects (n  8), and black bars represent obese T2D subjects (n  9).
Results represent means  SE, with each donor (n  8 –9) quantified from
8 wells/condition. *P  0.05 for T2D vs. lean myotubes. A: CO2 produc-
tion over 4 h from intracellular lipids (ICL). *Group effect, P  0.002;
overall differences between treatments, P  0.08. Post hoc analysis with
Bonferroni correction for “gf” vs. “GF,” P  0.02. B: fractional oxidation
of intracellular lipids (ICLOX), i.e., the ICLs that are oxidized in relation to
the total fatty acid availability in the cell [fatty acid oxidized/(cell-
associated fatty acids  fatty acids oxidized)]. *Group effect, P  0.002;
overall differences between treatments not significant. C: CO2 production
over 4 h from extracellular lipids (ECL). *Group effect, P  0.014; overall
differences between treatments, P  0.001. D: total CO2 production (from
intracellular and extracellular fatty acids). *Group effect, P  0.02; overall
differences between treatments, P  0.003. E: bars represent the difference
in ECLOX at high fatty acid availability in the “F” condition (100 M OA)
and low fatty acid availability in the “f” condition (5 M OA). Glucose
availability is indicated by “g” (0.1 mM glucose) or “G” (5 mM glucose).
Lean vs T2D; *P  0.04. F: bars represent the difference in total lipid
oxidation (TLOX) at high fatty acid availability in the F condition (100 M
OA) and low fatty acid availability in the f condition (5 M OA). Glucose
availability is indicated by g (0.1 mM glucose) or G (5 mM glucose). Lean
vs. T2D; *P  0.03. Differences between the 0.1 and 5.0 mM glucose were
not significant (g vs. G), P 
 0.50.
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case of an increased availability of extracellular fatty acids, the
oxidation of extracellular fatty acids is increased due to a mass
effect (Fig. 8C). This is demonstrated in the present in vitro
experiment (Fig. 4C) as well as in in vivo in high-fat feeding
studies (32, 33). However, we show that at the same time the
oxidation of fatty acids derived from ICL is suppressed. In this
way, increased extracellular fatty acid availability, also called
lipid overflow, may enhance intramyocellular lipid accumula-
tion despite an increase in ECLOX (Fig. 8C). From a physio-
logical point of view, this implies a phenotype in the initial
phases of obesity that displays increased fat oxidation in
parallel with increased IMTG and possibly increased insulin
resistance. Other in vivo observations support the hypothesis
that the oxidation of ICLs is increased when fatty acid avail-
ability is reduced and vice versa. Several human in vivo stable
isotope studies have investigated the use of TAG for fuel (35,
Fig. 5. Effects of glucose, OA, and carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) on the oxidation of intracellular lipids. The effects of extracellular substrates
and FCCP on the oxidation of intracellular lipids are expressed relative to the f or gf condition, which is set to 100%. Open bars represent myotubes from lean subjects (n
8), and black bars represent myotubes from obese T2D subjects (n  9), unless stated otherwise. Results represent means  SE, with each donor (n  8–9)
quantified from 4–8 wells/condition. For further explanation of abbreviations, see legend to Fig. 1. For absolute values, see Fig. 4A. A: increased fatty acid
availability is indicated by going from f (5 M OA) to F (100 M OA). Pairwise comparisons were performed with Bonferroni correction: gf vs. gF, P  0.001;
Gf vs. GF, P  0.001. aP  0.05 vs. the respective treatment set to 100%; *P  0.05 vs. lean subjects. B: increased glucose availability is indicated by going
from g to G. Pairwise comparisons were performed with Bonferroni correction: gf vs. Gf, P  0.04; gF vs. GF, P  0.14. aP  0.05 vs. the respective treatment
set to 100%. No differences between groups were found. C: oxidation of intracellular lipids with () and without () the mitochondrial uncoupler FCCP (1 M)
in gF and GF relative to the gf condition without FCCP. Open bars, lean without added FCCP; black bars, T2D without added FCCP; hatched bars, lean myotubes
in the presence of FCCP; checkered bars, T2D myotubes in the presence of FCCP. aP  0.05 vs. basal gf condition; n  6 donors/group, with each donor
quantified from 4 wells/condition. D: increase in CO2 production upon FCCP administration expressed in %same condition without FCCP (means  SE); n 
6 donors/group, with each donor quantified from 4 wells/condition. *P  0.05 for T2D vs. lean.
Fig. 6. Correlation between fasting respiratory quo-
tient (RQ) in vivo and lipid oxidation in the gF
condition in the myotubes in vitro. A low RQ ap-
proaching 0.7 indicates a relatively high fat oxidation,
whereas a high RQ approaching 1.0 indicates a low fat
oxidation.  Obese T2D subjects; Œlean subjects. r,
Spearman correlation coefficient; n  17. For further
explanation of abbreviations, see legend to Fig. 1.
A: correlation between ICLOX in the gF condition in
vitro and fasting whole body RQ. B: correlation be-
tween total lipid oxidation in the gF condition in vitro
and fasting whole body RQ.
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39). During exercise, an initial increase in the utilization of
TAG-derived fatty acids was observed. For a while after the
start of exercise, plasma FFA availability was increased due to
increased epinephrine-induced lipolysis, and this was paral-
leled by a decrease in TAG-derived FFA oxidation in skeletal
muscle. Inhibition of adipose tissue lipolysis with acipimox
decreased FFA availability from adipose tissue and increased
the oxidation of TAG-derived fatty acids during rest and
exercise (38). What these studies further support is that, under
restricted fatty acid availability, the contribution of ICLOX is
relevant for total fat oxidation. In human myotubes, both
exogenous and endogenous lipid sources are contributors to
total lipid oxidation (13).
Differences in the oxidation of IMCL may be caused by
differences in IMCL lipolysis. Some time ago, studies by
Wicklmayr et al. (42) suggested that lipolysis of intramyocel-
lular TAG, and therefore availability of fatty acids from the
intracellular lipid pool, is to a lesser extent under hormonal
control and may be more regulated by substrate supply. It was
suggested that product inhibition of hormone-sensitive lipase
by long-chain fatty acyl-CoA could lead to a decrease in IMCL
oxidation. In the present study, no differences in total lipolysis
were observed between high and low FFA availability, and
thus the effect of extracellular OA on ICLOX could not be
explained by changes in the ICL lipolysis rate.
When comparing myotubes from obese T2D individuals to
lean controls, the oxidation of both intracellular and extracel-
lular lipids was reduced, and the T2D myotubes showed a
lower ability to increase ECLOX and total lipid oxidation upon
increased fatty acid availability. It is suggested that the capac-
ity to increase fatty acid oxidation in adaptation to a high-fat
intake may be important to maintain insulin sensitivity, since it
may limit the formation of potential lipotoxic intermediates (1,
12, 22, 23, 28). In this study, a lower ICLOX as well as a lower
mitochondrial mass were independent factors related to a
higher cell-associated lipid accumulation. A lower lipid oxida-
tion, represented by a high-fasting RQ at the whole body level,
predisposed Pima Indians and nonobese men to obesity and
insulin resistance (34, 43). In myotubes established from young
healthy subjects, the capacity to increase fat oxidation in vitro
was positively related to insulin sensitivity in vivo (37). The
increase in fat oxidation in vitro was also related to a change in
RQ during a hyperinsulinemic euglycemic clamp. In the
present study, this correlation with a change in RQ could not be
replicated. Nevertheless, we also observed that a low lipid
oxidation in vivo, represented by a high RQ and measured
during fasting, was reflected by a low lipid oxidation in vitro,
Fig. 7. ICLOX correlates with mitochondrial mass in
lean but not T2D myotubes, and LD size is related to
cell-associated OA accumulation. A: mitochondrial
mass is related to the rate of ICLOX in lean myotubes
(Œ) only (Spearman’s r  0.94, P  0.005), but not
in obese T2D myotubes () or the group as a whole
(P  0.86). B: the amount of cell-associated OA in
the GF condition is positively related to LD size
(Spearman r  0.66, P  0.02). This correlation is
shown for the group as a whole (lean n  6, T2D
n  6) and analyzed with linear mixed-model anal-
ysis. For further explanation of abbreviations, see
Fig. 1. AU, arbitrary units.
Fig. 8. The oxidation of intracellular lipids is regulated by fatty acid availability
and reduced by lipid overflow. A: in healthy lean subjects, most of the fatty acids
taken up are shuttled toward oxidation. Intramyocellular lipid (IMCL) storage is
limited and in balance with IMCL utilization. B: in subjects with a reduced
oxidative capacity (e.g., T2D), fatty acids are shuttled toward storage, leading to an
increase in IMCL content. C: excess fatty acid availability (lipid overflow) initially
promotes fat oxidation but suppresses the use of IMCL-derived fatty acids, which
has a sparing effect on IMCL stores. This implicates that lower circulating fatty
acids may stimulate the oxidation of IMCL-derived fatty acids.
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in particular in myotubes from lean subjects. These observa-
tions suggest that the characteristics of the in vivo phenotype
are to a certain extent carried over to the myotubes in vitro by
either genetic or epigenetic mechanisms.
A molecular explanation for the impaired lipid oxidation in
myotubes established from obese T2D subjects may be found
in reduced mitochondrial function or number. Several studies
demonstrate a reduced mitochondrial mass and function in
muscle of lean, insulin-resistant offspring of T2D individuals
(27, 31), which may be related to a downregulation of perox-
isome proliferator-activated receptor- coactivator-1, as
shown in some (30) but not all (27) studies. In the present
study, mitochondrial mass was not related to ICLOX in the
myotubes established from obese T2D individuals. Moreover,
the uncoupling effect of FCCP in myotubes from T2D subjects
was slightly reduced compared with lean subjects. These find-
ings support a reduced mitochondrial capacity in primary
cultured myotubes. This is in line with a previous report where
we showed reduced activities of citrate synthase (14%) and
TCA cycle in myotubes from diabetic individuals compared
with lean, whereas the mitochondrial mass was not different
(14, 29).
In the present study, we compared myotubes established
from lean subjects with myotubes from obese T2D subjects to
optimize our conditions for finding significant differences. A
limitation of the study is that myotubes established from obese
nondiabetic subjects were not studied. Very recently, we
showed that myotubes established from obese subjects express
a reduced oxidation of endogenous lipids, whereas myotubes
established from obese T2D subjects express a reduced oxida-
tion of both endogenous and exogenous lipids (13).
In conclusion, extracellular lipid overflow may inhibit the
oxidation of IMCL, but this could not be explained by changed
lipolysis of IMCL in our study. Mitochondrial mass and the
rate of ICLOX contributed independently to IMCL accumula-
tion. Increased mitochondrial uncoupling by FCCP rescued the
reduction in ICLOX. This implicates that improved mitochon-
drial function and a reduction in circulating fatty acids, e.g., by
reduced adipose tissue lipolysis, may help to oxidize IMCL-
derived fatty acids. Furthermore, ICLOX, the ability to increase
extracellular lipid oxidation upon increased fatty acid avail-
ability and mitochondrial uncoupling were reduced in myo-
tubes from obese T2D individuals. Mitochondrial mass in
myotubes was not different between the two groups; however,
mitochondrial mass was related to ICLOX only in primary
cultured myotubes established from lean, not obese, T2D
individuals. This suggests that skeletal muscle fatty acid han-
dling is intrinsically impaired in obese T2D individuals.
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